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CPAN, a human nuclease regulated by the caspase-sensitive
inhibitor DFF45
Robert Halenbeck, Heather MacDonald, Anne Roulston, Timothy T. Chen,
Leah Conroy and Lewis T. Williams
Induction of apoptosis by death receptors such as Fas
or tumour necrosis factor (TNF) R1 leads to distinct
changes in cell morphology, activation of the caspase
protease cascade, and the degradation of nuclear
chromatin by activated nucleases. Here, we describe
the purification and cDNA cloning of a novel 40 kDa
endonuclease from Jurkat cells that is activated by
caspases. This protein, designated caspase-activated
nuclease (CPAN), is sufficient to degrade naked DNA
and to induce apoptotic morphology and DNA
fragmentation in naive nuclei. CPAN is highly
homologous to a recently described mouse nuclease,
CAD [1], and may represent the human homologue. Our
data on the human cDNA as well as additional data on
the mouse homologue suggest that a 30 amino-acid
portion of the recently published mouse sequence [1] is
incorrect. We show that the activity of human CPAN is
regulated by DFF45 [2], an inhibitor necessary for CPAN
expression and stabilization in an inactive state in
living cells. Proteolytic cleavage of DFF45 by caspases
in vitro leads to dissociation of DFF45 fragments from
CPAN and activation of CPAN as an endonuclease.
CPAN is a tightly regulated endonuclease with unique
characteristics that might represent a distinctive family
of endonucleases.
Address: Chiron Corporation, 4560 Horton Street, Emeryville,
California 94608, USA.
Correspondence: Robert Halenbeck
E-mail: rob_halenbeck@cc.chiron.com
Received: 23 February 1998
Revised: 19 March 1998
Accepted: 19 March 1998
Published: 13 April 1998
Current Biology 1998, 8:537–540
http://biomednet.com/elecref/0960982200800537
© Current Biology Ltd ISSN 0960-9822
Results and discussion
We have developed an in vitro apoptosis system that
mimics the later stages of the apoptotic cascade under cell-
free conditions. Addition of apoptotic cell extracts to naive
Jurkat nuclei induced chromatin condensation and the for-
mation of an internucleosomal DNA ‘ladder’ detected by
agarose gel electrophoresis. To study nuclease activation in
vitro, we added recombinant caspase-3 to normal Jurkat
cytosol and then measured DNA fragmentation in the in
vitro apoptosis assay and in a standard nuclease assay with
protein-free (naked) DNA. Addition of caspase-3 alone
(Figure 1a, lane 1) or Jurkat cell cytosol alone (Figure 1a,
lane 2) to naive Jurkat nuclei did not induce DNA frag-
mentation. When caspase-3 was added to cytosol,
however, substantial DNA fragmentation was observed
(Figure 1a, lane 3). When the same experiment was
repeated using naked human DNA instead of nuclei, a
similar result was obtained: addition of caspase-3 to cytosol
resulted in the apparent activation of an endonuclease to
degrade human DNA (Figure 1a, lane 8). These results
suggest that an inactive endonuclease present in cytosol is
activated by caspase-3 to degrade nuclear chromatin or
naked DNA in vitro. We have named the activated
endonuclease caspase-activated nuclease, or CPAN. 
To identify the active nuclease in cytosol, we fractionated
cytosol from 65 litres of Jurkat cells using a four-step pro-
cedure. On the final gel filtration column, activated CPAN
eluted as a single peak of nuclease activity (Figure 1b)
that correlated with the intensity of a 40 kDa band
(Figure 1c) resolved by SDS–PAGE. Using sequence data
derived from CPAN peptides, we isolated a full-length
cDNA clone (Figure 2a) encoding a 39,078 dalton protein
containing all seven peptide sequences determined from
the native protein. CPAN has no significant homology to
known nuclease protein families [3] and may, therefore,
represent a new class of endonuclease. CPAN is highly
homologous to the recently described mouse nuclease
CAD [1] and probably represents the human homologue.
Although the amino-acid sequences of human CPAN and
the reported mouse CAD are quite similar (71% identical),
there is a striking difference over 30 amino acids in the
central region of the sequences (Figure 2a). Peptide
sequencing of native CPAN across this region (peptide
III) confirms that the encoded protein sequence in the
CPAN cDNA is correct. To determine whether the
reported mouse CAD cDNA was also correct, we ampli-
fied the segment of the mouse gene in the region of the
discrepancy (nucleotides 80–280 in mouse CAD cDNA)
using five different tissue sources. In all five cases, the
products were identical but differed from the published
sequence by the deletion of three thymidine nucleotides
(Figure 2b). The amino-acid sequence predicted when
these nucleotides are deleted is 72% identical to the
human CPAN sequence in this region, whereas the pub-
lished sequence was only 7% identical (Figure 2c). It
seems likely that the published amino-acid sequence for
mouse CAD [1] is incorrect between residues 46–75. 
Recently, a protein complex known as DFF (DNA frag-
mentation factor) was described [2] with biochemical
activity similar to CPAN. DFF is an 80 kDa protein
complex comprising 40 kDa (DFF40) and 45 kDa
(DFF45) components. The cDNA for DFF45, but not for
DFF40, was reported. Our results suggest that CPAN
may be DFF40. First, inactive CPAN complex has an
apparent molecular weight similar to DFF. Second,
CPAN is activated by caspase-3 treatment but does not
contain any predicted caspase cleavage sites. We hypothe-
sized that CPAN is maintained in an inactive state by
binding to DFF45. Cleavage of DFF45 by caspases then
releases DFF45 and activates CPAN as an endonuclease. 
To examine whether CPAN alone is an active nuclease and
whether it associates with DFF45, we expressed CPAN and
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Characterization of activated CPAN. (a) Jurkat cytosol (25 µg) was
treated with caspase-3 and incubated with Jurkat nuclei (lanes 1–5) or
human DNA (lanes 6–10). Caspase-3 was treated with the caspase
inhibitor DEVD-fmk (50 µM) either before (labeled b) or after (labeled a)
addition to cytosol. After addition of nuclei or DNA, the samples were
incubated at 37ºC for 2 h, total DNA extracted, and then analyzed by
1% agarose gel electrophoresis. (b) Caspase-activated, poly(U)-
purified CPAN was subjected to gel filtration chromatography. The
indicated S-200 column fractions were tested for nuclease activity on
naked DNA and analyzed by 1% agarose gel electrophoresis. Molecular
weight standards are blue dextran 2000 (Vo) and BSA (67 kDa).
(c) Indicated column fractions were analyzed by SDS–PAGE visualized
by Coomassie staining. The arrow indicates purified, activated CPAN.
MW, molecular weight markers; LD, S-200 column load.
Figure 2
(a)
1 60
CPAN     MLQKPKSVKLRALRSPRKFGVAGRSCQEVLRKGCLRFQLPERGSRLCLYEDGTELTEDYF
mCAD  MCAV-RQ--C-----H -AC-----A-----L-----V-----MP-FPAVPVRRWHGGDGRLL
61									                122
CPAN  P SVPDNAELVLLTLGQAWQGYVSDIRRFLSAFHEPQVGLIQAAQQLLCDEQAPQRQRLLADL
mCAD -A-ET-H------T----V-N--HA-V----R---S-----L--K-----
123                                                         185
CPAN LHNVSQNIAAETRAEDPPWFEGLESRFQSKSGYLRYSCESRIRSYLREVSSYPSTVGAEAQEE
mCAD --H-----T----EQ--S---------RN--------------G------A-T-M-DEA----
186                                                         248
CPAN FLRVLGSMCQKLRSMQYNGSYFDRGAKGGSRLCTPEGWFSCQGPFDMDSCLSRHSINPYSNRE
mCAD Y-----------K-V-----------EAS-----------------LE----K------G---
249                                                         311
CPAN  SRILFSTWNLDHIIEKKRTIIPTLVEAIKEQDGREVDWEYFYGLLFTSENLKLVHIVCHKKTT
mCAD -------------------VV---A---Q-----N-----S----A--------A------
312                      338
CPAN HKLNCDPSRIYKPQTRLKRKQPVRKRQ
mCAD ---E--R----R---GSR----A--KRPARKR
-GPF-TTLSSYCF
(b)
(c)
112                                                         173
CPAN  CAGCTCCCTGAGCGCGGTT CCCGGCTGTGCCTGTACGAGGATGGCACGGAGCTGACGGAAGA
mCAD --------GAT--C-----T-------------------A------------G-------C--
174                                                225
CPAN TTACTTCCCCAGTGTT CCCGACAACGCCGAGCTGGTGCTGCT CACCTTGGGC
mCAD  C-G------GG-CC--T---A--G----T-----CC-AT----T----GCT---
26                                                           88
CPAN CQEVLRKGCLRFQLPERGSRLCLYEDGTELTEDYFPSVPDNAELVLLTLGQAWQGYVSDIRRF
mCAD  ---L-----V-----MP------------V-D-C--GL-ND---L----A-ET-H-----T--
121               140                                       183
184            200                        227      237
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Comparison of the sequences of human CPAN and mouse CAD
(mCAD). (a) The amino-acid residues in mCAD [1] that are identical to
those in human CPAN are indicated with a dash. Amino-acid residues
determined by peptide sequencing of purified native human CPAN are
underlined. The region of the mCAD sequence that is altered due to
frameshift errors is in bold and indicated with arrows. (b) The
nucleotide sequences for human CPAN and mCAD (GenBank
accession number AB009377) are compared in the region of the three
additional thymidines (T140, T200 and T227), each indicated with a
bar. (c) Amino acid alignment of the corrected mCAD sequence with
human CPAN in the region that was altered due to frameshift errors as
indicated by arrows. 
DFF45 in insect cells. Expression of KT3-tagged CPAN
alone failed to produce detectable protein by western blot
(data not shown). When CPAN was expressed in the pres-
ence of DFF45, however, significant quantities of CPAN
accumulated in the cell. Purification of CPAN through its
KT3 tag resulted in the recovery of a protein complex with
two bands resolved by SDS–PAGE (Figure 3a, lane 1), a
43.5 kDa band identified as DFF45 by western blot and a
40 kDa band identified as CPAN. Treatment of the
CPAN–DFF45 complex with caspase-3 cleaved DFF45 at
two sites generating three peptide fragments (Figure 3a,
lane 2), consistent with published data on DFF45 [2]. The
activated CPAN–DFF45 complex was purified by affinity
chromatography using poly(U)–Sepharose (see Supplemen-
tary material). Fragments of DFF45 were not bound by the
poly(U) resin and flowed through the column (Figure 3a,
lane 3). CPAN, however, was selectively bound by the resin
and eluted in a highly purified form free of any associated
DFF45 fragments (Figure 3a, lane 4). 
To assess the activity of CPAN during the poly(U) purifi-
cation, we measured DNA fragmentation in an in vitro
apoptosis assay. Prior to caspase-3 activation, the purified
CPAN–DFF45 complex was inactive (Figure 3b, lane 1).
Following caspase-3 treatment, the complex was active at
degrading nuclear chromatin (Figure 3b, lane 2). When the
activated complex was purified on the poly(U) column,
essentially all of the nuclease activity bound to the poly(U)
column (Figure 3b, lane 3) and eluted with the purified
CPAN protein (Figure 3b, lane 4). The nuclease activity of
CPAN was resistant to the caspase inhibitors zVAD-fmk
and DEVD-fmk (Figure 3b, lane 5). These results indicate
that caspase-3 activates the DFF45–CPAN complex by
cleaving DFF45 and releasing DFF45 fragments from
CPAN. In its activated form, purified recombinant CPAN
alone was sufficient to induce apoptotic morphology and
DNA fragmentation in naive nuclei in vitro.
The specific activity of recombinant CPAN
(1.2 × 106 U/mg) was similar to that of the purified native
CPAN when tested in the in vitro apoptosis assay. In a
spectrophotometric Kunitz assay [4], CPAN was shown to
have approximately equivalent specific activity
(2.5 × 108 U/mg) to that of bovine pancreatic DNase I [4].
The biochemical characteristics of the poly(U)-purified
CPAN were analyzed in a nuclease assay. CPAN was
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Purification and characterization of recombinant CPAN.
(a) SDS–PAGE analysis of the KT3-purified CPAN/DFF45 complex
(lane 1), the caspase-3-treated complex (lane 2), the poly(U)
flowthrough of the caspase-3-treated complex (lane 3), and the
corresponding poly(U) eluate (lane 4). Proteins were visualized with
Coomassie stain. (b) The samples described in (a) were incubated in
the in vitro apoptosis assay. The poly(U) eluate was assayed without
(lane 4) and with (lane 5) the addition of 25 µM of the caspase
inhibitors zVAD-fmk and DEVD-fmk. After 2 h at 37°C, total genomic
DNA was extracted and analyzed by 1% agarose gel electrophoresis.
(c) Purified CPAN was tested in the standard nuclease assay with and
without added BSA and sodium chloride. The effect of EDTA (1 mM),
or EDTA plus Mg2+ (4 mM), Ca2+ (4 mM) or Mn2+ (4 mM) was tested.
The activity of CPAN in the presence of Mg2+ (2 mM) combined with
Ca2+ (4 mM), Zn2+ (1 mM), ATA (100 µM) or globular actin
(100 µg/ml) is shown.
found to be significantly less active when assayed in the
absence of the carrier protein bovine serum albumin (BSA)
and salt (Figure 3c). CPAN was also found to be magne-
sium or manganese dependent and inhibited by zinc and
aurintricarboxylic acid (ATA), but not by globular actin. 
The results presented here demonstrate that CPAN associ-
ates with DFF45 in an inactive nuclease complex that is
similar to the native DFF complex, suggesting that CPAN
may be equivalent to DFF40. However, activated native
DFF was reported to be inactive as a nuclease when tested
on naked DNA [2]. We have shown that the nuclease activity
of CPAN required the presence of magnesium ions, sodium
chloride, and a carrier protein such as BSA. When native
DFF was tested for nuclease activity, the assay conditions
involved low levels of magnesium ions and salt with no BSA
added. Such conditions could significantly reduce the appar-
ent nuclease activity of DFF to less than detectable levels. 
In this report, we describe the discovery of a human
endonuclease activated in apoptosis by the proteolytic
action of caspases. Through its association with the caspase-
sensitive inhibitor DFF45, CPAN activation is dependent
on the activation of the cysteine protease cascade.
Inhibitors of apoptotic cell death have been shown to block
apoptosis through the inhibition of caspases [5,6]. Once cas-
pases have activated CPAN, however, these inhibitors can
no longer block the fragmentation of genomic DNA as the
nuclease activity of CPAN is unaffected. Therefore, CPAN
activation represents a critical event that occurs down-
stream of caspases and results in the destruction of nuclear
chromatin, the hallmark of the apoptotic program. 
Materials and methods
Assay for CPAN activity
CPAN activity was determined using an in vitro apoptosis assay or a
nuclease assay. Fractions containing inactive CPAN were incubated with
caspase-3 (25 ng) for 30 min at 25°C in 20µl of buffer A (10 mM Hepes
pH 7.4, 50 mM sodium chloride, 2 mM MgCl2, 5 mM EGTA, 1 mM DTT)
containing 0.83 mM ATP, 8.3 mM creatine phosphate, 33.2µg/ml crea-
tine kinase. Naive Jurkat nuclei (5µl, 6.5 × 105 total), prepared essentially
as described in [7], were added and incubated for 1–2 h at 37°C. The
percentage of apoptotic nuclei was determined microscopically using
Hoechst 33258 stain. DNA fragmentation was determined by extraction
of genomic DNA [8] and analysis by 1% agarose gel electrophoresis
visualized with ethidium bromide. For measuring nuclease activity, acti-
vated fractions were incubated in buffer (10µl, 10 mM Hepes pH 7.4,
4 mM MgCl2, 4 mM DTT, 5 mM EGTA, 1 mg/ml BSA and 75 mM sodium
chloride) with human genomic DNA (1µg, Promega), incubated for
1–2 h at 30°C, and then analyzed by 1% agarose gel electrophoresis.
cDNA cloning and expression of CPAN and DFF45
Degenerate oligonucleotide primers 5′-GCNTTYCAYGARCCICAR-
GTIGG-3′ and 5′-TGIGGIGCYTGYTCRTCRCA-3′ designed from the
sequence of CPAN peptide IV were used to amplify a 72 bp nucleotide
fragment of CPAN by PCR from a placenta cDNA library (Clontech
Marathon-Ready). Based on this sequence, nested PCR was per-
formed using the same placenta cDNA library. A 400 bp fragment was
obtained, labeled with 32P using an Amersham Rediprime kit, and used
to screen 3 × 106 clones of a bone-marrow library prepared in a ZapEx-
press II λgt10 phage (Stratagene) plated on XL1-MRF′ Blue cells. Two
clones were identified, one of which (clone 11) was full length (3.3 kb)
encoding the amino-terminal sequence of CPAN. DNA sequence
analysis of clone 11 revealed that the CPAN open reading frame was
interrupted by two insertions that introduced two frameshifts and a
stop codon. To identify a complete CPAN clone lacking insertions, the
primers 5′-GCGAGGACGGATCTGAGCAGCTGGGCAG-3′ and 
5′-AAATGATGCCCACGTCAGGCCTCAAACA-3′ were used to amplify
the CPAN coding region by PCR from human leukocyte and HeLa cDNA
libraries (Clontech) and from first-strand cDNA reverse-transcribed from
oligo(dT)-primed total human pancreas RNA (Clontech). Full-length
CPAN cDNA (GenBank accession number AF039210) from pancreas
was PCR amplified using primers that included a KT3 tag in-frame at the
carboxyl terminus of the CPAN sequence. The KT3-tagged CPAN insert
was subcloned into the pFASTBAC donor plasmid (GIBCO BRL).
The full-length DFF45 cDNA was PCR amplified from a human liver
cDNA library (Gibco, BRL) with an in-frame Glu tag at the carboxyl ter-
minus and a His6 tag at the amino terminus. The His6–Glu-tagged
DFF45 baculovirus was generated via the BacPAK-His2 transfer vector
(Clontech). Recombinant protein was obtained from suspension cul-
tures of 1.5 × 106 Sf9 cells per ml infected at a multiplicity of infection
of 1–5 for 72 h at 25°C in serum-free media.
cDNA cloning of murine CAD
The sequence of murine CAD was verified from three independent RNA
sources, thymus (CD1 mouse), spleen (BALB/c mouse; Clontech), and L-
929 cells (C3H mouse), and from two cDNA library sources, brain
(BALB/c; Clontech) and 14 day embryo (CD1 mouse). RNA was reverse
transcribed using an oligo(dT) primer and the Gene Amp RNA PCR kit
(Perkin Elmer) according to manufacturer’s instructions. Products from the
reverse transcription reaction and mouse libraries were PCR amplified
using the primers 5′-TTGCGAGCCCTACATAGC-3′ and 5′-CAGTAG-
GTCCGACGTGCC-3′ and then sequenced directly in both directions.
Supplementary material
Additional methodological details are available as Supplementary mate-
rial published with this article on the internet.
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Purification of CPAN 
Jurkat T cells (65 litres) were harvested, resuspended at 2 × 108
cells/ml in buffer A containing 10 mM EDTA, 200 µM PMSF, and
2 µg/ml leupeptin, lysed by four freeze/thaw cycles, and centrifuged for
10 min at 10,000 × g, then at 100,000 × g for 30 min. The clarified
cytosol was made 0.25 M sucrose and then dialyzed into 10 mM
Hepes pH 7.2, 0.25 M sucrose, 2 mM MgCl2, 5 mM EGTA, 5 mM
EDTA, 2 mM DTT, 200 µM PMSF and 2 µg/ml leupeptin, loaded on a
SP Sepharose HP column (Pharmacia, 2.6 × 25 cm) and eluted with a
330 ml 0–0.6 M sodium chloride gradient. Active fractions were pooled
and subjected to gel filtration chromatography on an Sephacryl S-200
column (5 × 85 cm) equilibrated in buffer C (10 mM Hepes pH 7.4,
0.25 M sucrose, 150 mM sodium chloride, 5 mM EGTA, 2 mM MgCl2,
and 2 mM DTT). Active fractions were passed two times through a
poly(U)–Sepharose column (1.6 × 15 cm) equilibrated in buffer C. The
unbound fraction was activated by treatment with caspase-3
(128 ng/ml) for 16 h at 20°C, and loaded onto a second poly(U)
Sepharose column (1.6 × 15 cm) eluted with a 80 ml 0–1.5 M sodium
chloride gradient in buffer C. Active fractions were pooled and resolved
by gel filtration chromatography (#2) on a Sephacryl S-200 column
(0.9 × 33 cm) equilibrated in buffer C. Fraction aliquots were analyzed
for in vitro apoptosis activity (0.5 µl), nuclease activity (2 µl), and by
SDS–PAGE (12%) following lyophilization of selected column frac-
tions (200 µl) dialyzed into 5 mM phosphate buffer pH 7.0 containing
0.1% SDS and 1 mM DTT. CPAN was further purified by preparative
SDS–PAGE and subjected to protein sequence analysis following
digestion with Lys-C. Additional protein sequence data were obtained
at the Rockefeller University Protein/DNA Technology Center [S1]. 
Purification and characterization of recombinant CPAN
The KT3–CPAN baculovirus was infected alone or with the
His6–DFF45–Glu baculovirus in Sf9 insect cells and harvested at 72 h.
The cells from both cultures were solubilized in buffer B (buffer A with
sodium chloride added to 150 mM, 1% Triton X-100, 200 µM PMSF,
and 2 µg/ml leupeptin) and clarified by centrifugation (10,000 × g for
10 min at 4°C). The CPAN–DFF45 lysate was loaded on a KT3 mono-
clonal antibody column (3 ml) and CPAN eluted with a KT3 peptide
(100 µg/ml). Caspase-3 (2 µg) and DTT (2 mM) were added to the
eluate and incubated for 3.5 h at 20°C. The activated CPAN was
loaded onto a poly(U)–Sepharose column and eluted with a 0–1 M
sodium chloride gradient in buffer A. Active CPAN was stabilized with
0.2 mg/ml BSA and stored at 4°C.
Reference
S1. Fernandez J, Andrews L, Mische SM: An improved procedure for
enzymatic digestion of polyvinylidene difluoride-bound proteins
for internal sequence analysis. Anal Biochem 1994, 218:112-118.
Supplementary material
Table S1
Purification of activated CPAN from Jurkat cells.
Total Specific Total
protein activity activity Recovery Purification
Step Fraction (mg)* (units/mg)† (unit) (%) (-fold)
1 Cytosol 5632 54 305250 100 1
2 S-Sepharose 440 418 183736 60 8
3 S-200 1 93 1290 119050 39 24
4 Poly(U) FT 2‡ 66 2125 140625 46 39
5 Poly(U) eluate 0.1 625,000 64000 21 11,530
6 S-200 2 0.006 625,000 3520 1.2 11,530
Cytosol from 65 litres of Jurkat cells was purified as described in
Materials and methods. *Protein concentration was determined using
the BCA Protein Reagent method (Pierce) except for the S-200 2 pool
which was estimated based on SDS–PAGE band intensity using
Coomassie stain. †Units of CPAN activity were determined by
measuring the apoptotic activity of serial dilutions of the purification
samples in the in vitro apoptosis assay quantitated microscopically
using Hoescht stain. One unit was arbitrarily defined as the amount of
CPAN required to cause 50% apoptotic cells in 6.5 × 105 total Jurkat
nuclei in a 25 µl reaction. ‡The poly(U) FT 2 fraction indicates the
S-200 1 pool that had been passed through a poly(U) column twice.
FT, flowthrough.
